Page 6 - Scientific Library
Return of SIRT1 deacetylase - Why is SIRT1 so attractive in Drug discovery and Stem cell research?
Mutant or wild-type: 7 effective means to screen and profile Human EZH2 Methyltransferase
Histone-lysine N-methyltransferase EZH2  is a methyltransferase involved in transcriptional gene regulation. Together with with EED, RbAP48, SUZ12 and AEBP2, EZH2 forms a 5-member complex that adds
Immunotherapy Screening - B7-1 / CD28 and B7-1 / CTLA4 Pathways in Drug Discovery
The treatment of diseases by inducing, enhancing, or surpressing an immune response is referred to as Immunotherapy. T-cell activation and inactivation requires the coordination of various co-inhibitory
Immunotherapy Screening - A focus on PD-1/PD-L1/PD-L2 Pathway in drug discovery
The treatment of diseases by inducing, enhancing, or surpressing an immune response is referred to as Immunotherapy. T-cell activation and inactivation requires the coordination of various co-inhibitory
Immunotherapy - BLTA:HVEM, CD47:SIRPα in drug discovery
The treatment of diseases by inducing, enhancing, or surpressing an immune response is referred to as Immunotherapy. T-cell activation and inactivation requires the coordination of various co-inhibitory
Immunogenicity in biotherapeutics and biosimilars
Following on from my previous post on biosimilars and biotherapeutics (or biologics), let's now take a look at some of the specific criteria for this kind of compound, which are not normally required
Proteasome inhibitor approved by FDA for Myeloma retreatment
The U.S. Food and Drug Administration (FDA) has approved Velcade (Bortezomib) for the retreatment of adult patients with Multiple Myeloma who had previously responded to Velcade therapy and relapsed
Epigenetics Writers - Readers - Erasers: Targeting Writers in Drug Discovery
Epigenetic modifications target DNA and Histone proteins.
One of the roles of Epigenetics is to drive cellular differentiation from totipotent Stem cells to fully differentiated cell types, by regulating